Go to
JCI Insight
Citations to this article
Camille Guillerey, … , Mark J. Smyth, Ludovic Martinet
Published June 15, 2015
Citation Information: J Clin Invest. 2015;125(7):2904-2904. https://doi.org/10.1172/JCI82646.
Citation Information: J Clin Invest. 2015;125(7):2904-2904. https://doi.org/10.1172/JCI82646.
Abstract
Authors
Camille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, Kim Miles, Shin Foong Ngiow, Michelle C.R. Yong, Michele W.L. Teng, Marco Colonna, David S. Ritchie, Marta Chesi, P. Leif Bergsagel, Geoffrey R. Hill, Mark J. Smyth, Ludovic Martinet
Total citations by year
Citation information
Citations to this article (29)
| Title and authors | Publication | Year |
|---|---|---|
|
Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.
Kim S, Chung H, Kwak JE, Kim YR, Park CH, Kim Y, Cheong JW, Wu J, Shin EC, Cho H, Kim JS |
Journal for ImmunoTherapy of Cancer | 2024 |
|
CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K, Li L, Han G |
Frontiers in Endocrinology | 2024 |
|
Immune status and selection of patients for immunotherapy in myeloma: a proposal
Dhodapkar MV |
Blood Advances | 2024 |
|
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
Chen S, Zhu H, Jounaidi Y |
Signal Transduction and Targeted Therapy | 2024 |
|
Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade
Tian W, Qin G, Jia M, Li W, Cai W, Wang H, Zhao Y, Bao X, Wei W, Zhang Y, Shao Q |
Frontiers in immunology | 2023 |
|
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
M Swamydas, E Murphy, J Ignatz-Hoover, E Malek, J Driscoll |
Journal of Hematology & Oncology | 2022 |
|
The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion
Pichler AC, Cannons JL, Schwartzberg PL |
Frontiers in immunology | 2022 |
|
Innate lymphoid cells in early tumor development
Warner K, Ghaedi M, Chung DC, Jacquelot N, Ohashi PS |
Frontiers in immunology | 2022 |
|
Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
L Lemaitre, M Hamaidia, J Descamps, L Ferreira, M Joubert, M Gadelorge, H Avet-Loiseau, A Justo, N Reina, F Deschaseaux, L Martinet, P Bourin, J Corre, N Espagnolle |
Blood Advances | 2022 |
|
The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception
Dhodapkar MV |
American Journal of Hematology | 2022 |
|
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
Y Wang, L Xu, W Zhao, X Chen, L Wen, W Duan, XJ Yu, FD Zhou, Y Liu, J Hao, X Huang, J Lu, Q Ge |
Clinical and Translational Medicine | 2021 |
|
Single-cell RNA-sequencing reveals distinct immune cell subsets and signaling pathways in IgA nephropathy
H Zeng, L Wang, J Li, S Luo, Q Han, F Su, J Wei, X Wei, J Wu, B Li, J Huang, P Tang, C Cao, Y Zhou, Q Yang |
Cell & Bioscience | 2021 |
|
Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma
M Pisano, Y Cheng, F Sun, B Dhakal, A DSouza, S Chhabra, JM Knight, S Rao, F Zhan, P Hari, S Janz |
Frontiers in immunology | 2021 |
|
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
EW Meermeier, SJ Welsh, ME Sharik, MT Du, VM Garbitt, DL Riggs, CX Shi, CK Stein, M Bergsagel, B Chau, ML Wheeler, N Bezman, F Wang, P Strop, PL Bergsagel, M Chesi |
2021 | |
|
Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor
A Mekhloufi, A Kosta, H Stabile, R Molfetta, A Zingoni, A Soriani, M Cippitelli, R Paolini, A Gismondi, MR Ricciardi, MT Petrucci, L Masuelli, G Caracciolo, S Palchetti, A Santoni, C Fionda |
Cancers | 2020 |
|
EFFICIENCY OF BONE MARROW PRECURSOR CELL COLONY-FORMING AS A PREDICTOR OF DISEASE COURSE IN PLASMA CELL MYELOMA PATIENTS WITH A HISTORY OF RADIATION EXPOSURE
Z Minchenko, T Liubarets, V Balan, O Dmytrenko, T Shlyakhtichenko, V Moyseyenko, Y Silayev, V Bebeshko |
2020 | |
|
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
S Akhtar, TA Ali, A Faiyaz, OS Khan, SS Raza, M Kulinski, HE Omri, AA Bhat, S Uddin |
International journal of molecular sciences | 2020 |
|
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease
O Lucar, RK Reeves, S Jost |
Frontiers in immunology | 2019 |
|
NK Cell Dysfunction and Checkpoint Immunotherapy
J Bi, Z Tian |
Frontiers in immunology | 2019 |
|
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
H Liu, J He, SP Koh, Y Zhong, Z Liu, Z Wang, Y Zhang, Z Li, BT Tam, P Lin, M Xiao, KH Young, B Amini, MW Starbuck, HC Lee, NM Navone, RE Davis, Q Tong, PL Bergsagel, J Hou, Q Yi, RZ Orlowski, RF Gagel, J Yang |
Science Translational Medicine | 2019 |
|
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
TG Martin, K Corzo, M Chiron, H van de Velde, G Abbadessa, F Campana, M Solanki, R Meng, H Lee, D Wiederschain, C Zhu, A Rak, KC Anderson |
Cells | 2019 |
|
Mouse models of multiple myeloma: technologic platforms and perspectives
M Rossi, C Botta, M Arbitrio, RD Grembiale, P Tagliaferri, P Tassone |
Oncotarget | 2018 |
|
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
B Zitti, R Molfetta, C Fionda, L Quatrini, H Stabile, M Lecce, V Turris, MR Ricciardi, MT Petrucci, M Cippitelli, A Gismondi, A Santoni, R Paolini |
Scientific Reports | 2017 |
|
High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma
G Bernardini, E Vulpis, V Bonanni, H Stabile, MR Ricciardi, MT Petrucci, A Gismondi, A Santoni, A Zingoni |
Leukemia & Lymphoma | 2017 |
|
Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis
ET Gross, S Han, P Vemu, CD Peinado, M Marsala, LG Ellies, JD Bui |
OncoImmunology | 2016 |
|
Preclinical animal models of multiple myeloma
ST Lwin, CM Edwards, R Silbermann |
BoneKEy Reports | 2016 |
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
M Boyiadzis, MR Bishop, R Abonour, KC Anderson, SM Ansell, D Avigan, L Barbarotta, AJ Barrett, KV Besien, PL Bergsagel, I Borrello, J Brody, J Brufsky, M Cairo, A Chari, A Cohen, J Cortes, SJ Forman, JW Friedberg, EJ Fuchs, SD Gore, S Jagannath, BS Kahl, J Kline, JN Kochenderfer, LW Kwak, R Levy, M Lima, MR Litzow, A Mahindra, J Miller, NC Munshi, RZ Orlowski, JM Pagel, DL Porter, SJ Russell, K Schwartz, MA Shipp, D Siegel, RM Stone, MS Tallman, JM Timmerman, FV Rhee, EK Waller, A Welsh, M Werner, PH Wiernik, MV Dhodapkar |
Journal for ImmunoTherapy of Cancer | 2016 |
|
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
C Fionda, MP Abruzzese, A Zingoni, F Cecere, E Vulpis, G Peruzzi, A Soriani, R Molfetta, R Paolini, MR Ricciardi, MT Petrucci, A Santoni, M Cippitelli |
Oncotarget | 2015 |
|
Reference Module in Biomedical Sciences
DL Sackett, RB Haynes |
2014 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)